A humble, decades-old folate compound — used not to fight cancer but to ease the side effects of chemotherapy — has become the latest flashpoint in America’s health wars.

On September 10, the Trump administration announced that the FDA would move toward approving leucovorin for children with cerebral folate deficiency, a rare metabolic disorder linked to autism in some cases. Supporters hailed it as long-overdue recognition of promising small studies; critics called it another example of the MAHA agenda politicizing science.

While bureaucrats and scientists bicker, families with real skin in the game tirelessly run their own experiments and share their results, hoping the science will eventually catch up.

The debate since has been fierce, with professional groups such as the American

See Full Page